Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 17/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23875079 | 0.86 | CCNT1 (0.42) | — | |
| SCHEMBL21884374 | 0.81 | CCNT1 (0.40) | WDR5 | |
| SCHEMBL21884660 | 0.81 | CCNT1 (0.40) | — | |
| SCHEMBL24066323 | 0.80 | WDR5 (0.40) | WDR5NISCH | |
| SCHEMBL21884435 | 0.77 | ALDH1A1 (0.36) | WDR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL23875006 | 0.76 | SLC9A1 (0.37) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21884444 | 0.75 | PYGL (0.40) | PNLIPMEN1ALDH1A1GLAKMT2A | |
| SCHEMBL21884371 | 0.75 | ABL1 (0.36) | WDR5NISCH | |
| SCHEMBL24066342 | 0.75 | PGR (0.39) | WDR5NISCH | |
| SCHEMBL21884401 | 0.74 | WDR5 (0.36) | WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | WDR5 3394/4885NISCH 1713/4885PNLIP 952/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | WDR5 1567/4885NISCH 4403/4885PNLIP 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.